Navigation Links
Tengion to Present at the 13th Annual BIO CEO & Investor Conference and the Leerink Swann 'Hot Topics in Therapeutics' Roundtable Conference
Date:2/7/2011

EAST NORRITON, Pa., Feb. 7, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN), a leader in regenerative medicine, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion, will present at the upcoming 13th Annual BIO CEO & Investor Conference on Monday, February 14, 2011, at 2:00 p.m. EST.  Dr. Nichtberger will also participate in a panel discussion titled "IPO Window-Creaking Open or Wide Open?" the following day on Tuesday, February 15, 2011, at 1:30 p.m. EST.  


Dr. Nichtberger will also be presenting at the upcoming Leerink Swann "Hot Topics in Therapeutics" Roundtable Conference on Wednesday, February 16, 2011, at 9:35 a.m. EST.  Dr. Nichtberger will also participate in the Emerging Platforms panel discussion at 10:45 a.m. EST that same day.  


Replays of both webcasts will be available in the Investors section of the Company's at www.tengion.com.  Investors interested in listening to any live webcast are advised to log on before the start time in order to download any required software.

About Tengion

Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform™ that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion's product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. An initial clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal.  The Company's lead preclinical program is the Neo-Kidney Augment™, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure.  Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment™ for the treatment of neurogenic bladder.  Tengion has worldwide rights to its product candidates. For more information, please visit www.tengion.com.


'/>"/>
SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Tengion Presents New Large Animal Data Demonstrating Functional Kidney Regeneration at the American Society for Transplantation Annual Conference
2. Tengion Appoints Richard E. Kuntz, MD to its Board of Directors
3. Tengion Announces Webcast of Analyst and Investor Meeting on October 27, 2010
4. Tengion Appoints A. Brian Davis Chief Financial Officer
5. Tengion Presents New Data Supporting its Organ Regeneration Platform™ at 8th Annual Meeting of the International Society for Stem Cell Research
6. Tengion Presents New Data Supporting Key Urologic and Kidney Programs at 16th Annual Meeting of the International Society for Cellular Therapy
7. Tengion to Present at the Piper Jaffray 20th Annual Healthcare Conference
8. Tengion Announces Second Closing of Series C Financing
9. Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association
10. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
11. Celtic Pharma Announces Presentation of Preclinical Data at the 69th Annual Meeting of the AAD in New Orleans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global ... industries to improve patient outcomes and quality of life, will now be offering ... being attributed to new regulatory requirements for all new drug products, including the ...
(Date:10/11/2017)... ... October 11, 2017 , ... Personal eye wash is a basic first aid supply for any ... So which eye do you rinse first if a dangerous substance enters both eyes? It’s ... Wash with its unique dual eye piece. , “Whether its dirt and debris, or ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... San Diego-based ... of its corporate rebranding initiative announced today. The bold new look is part ... as the company moves into a significant growth period. , It will also expand ...
Breaking Biology Technology:
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... 30, 2017 Trends, opportunities and forecast in ... by technology (fingerprint, AFIS, iris recognition, facial recognition, hand ... by end use industry (government and law enforcement, commercial ... banking, and others), and by region ( North ... Asia Pacific , and the Rest of ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
Breaking Biology News(10 mins):